Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 1

Conditions

Hematologic Neoplasms 2Pseudomonas Infections 1Pneumonia 1Gram-Negative Bacterial Infections 1Febrile Neutropenia 1Bacteremia 1

Interventions

Cytarabine 34Cyclophosphamide 21Vincristine 20Methotrexate 18Dexamethasone 18Mercaptopurine 16Idarubicin 16nilotinib 15Daunorubicin 15Imatinib Mesylate 13fludarabine 12Granulocyte Colony-Stimulating Factor 12Asparaginase 12Rituximab 11Doxorubicin 10Prednisolone 9Etoposide 8Prednisone 7Thioguanine 6Teniposide 6Mitoxantrone 6Dasatinib 6venetoclax 5fludarabine phosphate 5Vindesine 5Stem Cell Transplantation 5Ifosfamide 5Azacitidine 4posaconazole 3pirtobrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × ceftolozane, tazobactam drug combination × Other hematologic neoplasm × Clear all
NCT04673175 2026-01-21

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

Weill Medical College of Cornell University

Phase 4 Terminated
17 enrolled 20 charts
Other hematologic neoplasm

Pneumonia, Pseudomonas Infections, Bacteremia, Gram-Negative Bacterial Infections, Hematologic Neoplasms

NCT05061654 2023-08-14

CEF-10

Hamad Medical Corporation

Phase 4 Withdrawn
Classical hematologyOther hematologic neoplasm

Hematologic Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡